The Handgrip That Predicts Your Patient’s Cardiac Future

Dr Edward Leatham, Consultant Cardiologist  |  Surrey Cardiovascular Clinic  |  April 2026

For busy people, or to tune in when on the move, Google Notebook AI audio podcast are available as a story beneath.

Grip strength measurement reveals muscle-metabolic dysfunction that drives cardiovascular disease through inflammatory pathways more predictably than traditional risk factors.

I measure grip strength in every patient because it provides immediate insight into cardiovascular risk that often exceeds expensive investigations. This simple test reflects the functional integrity of skeletal muscle as an endocrine organ, revealing inflammatory status and metabolic health that directly influence coronary outcomes.[1] The evidence now compels us to recognise muscle function as a primary therapeutic target in cardiovascular prevention.[2]

Background

The paradigm shift began when I noticed that my strongest patients rarely suffered heart attacks, regardless of their cholesterol levels or blood pressure readings. This clinical observation, initially dismissed as coincidental, has evolved into one of the most important diagnostic tools in my cardiovascular practice. Grip strength measurement now occupies the same clinical importance as electrocardiography in my assessment routine, providing immediate insight into systemic health that transforms therapeutic decision-making.[3]

The mechanistic foundation centres on skeletal muscle functioning as a vast endocrine organ, constantly secreting chemical messengers that either protect or damage the cardiovascular system.[8] When patients maintain strong, functionally competent muscle tissue, they benefit from continuous secretion of protective myokines including irisin, cathepsin B, and musclin.[15,17] These bioactive molecules cross into systemic circulation, directly combating atherosclerosis through multiple pathways. Irisin enhances endothelial nitric oxide production, improving arterial compliance and reducing thrombotic risk.[17] Cathepsin B crosses the blood-brain barrier, stimulating brain-derived neurotrophic factor production that protects both neuronal and vascular tissues from oxidative damage.[16] Musclin improves insulin sensitivity throughout peripheral tissues, preventing the hyperglycaemia and advanced glycation end-product formation that accelerate coronary disease progression.[14]

Conversely, declining muscle strength signals the collapse of this protective network.[9] Dynapenic patients lose the ability to secrete adequate quantities of protective myokines while simultaneously increasing production of inflammatory mediators including myostatin, GDF-15, and activin A. This creates a perfect storm for cardiovascular disease progression. Myostatin directly promotes insulin resistance and visceral adipose tissue accumulation, the primary driver of coronary inflammation that I observe accelerating in clinical practice.[14] GDF-15 elevation correlates with increased major adverse cardiovascular events, reflecting the systemic inflammatory state that weak muscles perpetuate.[6]

The grip strength measurement serves as our window into this complex biological network because hand muscles reflect the functional status of skeletal muscle throughout the body.[4] When I record declining grip strength over serial consultations, I am witnessing the real-time collapse of muscle-mediated cardiovascular protection. This occurs years before traditional risk factors demonstrate meaningful changes, providing an early warning system for accelerating disease progression that fundamentally alters my therapeutic approach.[6]

The Evidence

The evidence base connecting grip strength to cardiovascular outcomes has reached compelling levels that now influence my daily clinical practice. The landmark PURE study, following over 140,000 participants across seventeen countries over median four-year follow-up, demonstrated that grip strength predicts cardiovascular mortality more accurately than systolic blood pressure.[1] Each 5kg decline in grip strength correlated with 17% increased risk of cardiovascular death, 7% increased risk of myocardial infarction, and 9% increased risk of stroke, independent of traditional risk factors including age, education, employment status, smoking, alcohol consumption, diabetes, and hypertension.[1]

The UK Biobank data provides even more compelling evidence, following nearly half a million participants over extended observation periods.[2] Participants with grip strength in the lowest quintile demonstrated 16% increased risk of cardiovascular death compared to those in the highest quintile, with hazard ratios remaining significant after adjustment for established cardiovascular risk factors.[2] Crucially, this relationship proved linear across the entire grip strength spectrum, meaning that every incremental improvement in muscle function translates into measurable cardiovascular protection.[2]

The mechanistic studies reveal why these associations reflect causation rather than mere correlation.[8] Patients with declining grip strength demonstrate elevated inflammatory markers including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha precisely the mediators that drive atherosclerotic plaque formation and acute coronary syndromes.[16] Recent research has identified the biological pathway connecting muscle weakness to vascular inflammation through dysregulated myokine secretion.[15] Weak muscles produce insufficient quantities of irisin, the myokine responsible for maintaining endothelial function and arterial compliance.[17] Simultaneously, they oversecrete inflammatory myokines that directly damage arterial walls and promote plaque instability.[16]

The Mendelian randomisation studies provide the most convincing evidence for causation.[3] Genetic variants associated with reduced muscle strength independently increase cardiovascular disease risk, suggesting the relationship is causal rather than simply associative. Individuals carrying genetic polymorphisms that reduce muscle function demonstrate increased coronary artery calcium scores and accelerated atherosclerosis progression, even when traditional risk factors remain optimal.[3]

Intervention trials complete the evidentiary framework.[11] Progressive resistance training programs that specifically improve grip strength demonstrate measurable improvements in flow-mediated dilatation, arterial stiffness, and inflammatory marker profiles within twelve weeks.[13] These changes occur independently of weight loss or aerobic fitness improvements, confirming that muscle strength itself provides cardiovascular protection through distinct biological pathways that we can target therapeutically.[13]

Clinical Implications

This evidence has fundamentally transformed my approach to cardiovascular risk assessment and therapeutic intervention. I now measure grip strength using a calibrated handgrip dynamometer in every consultation, recording the best of three attempts from the dominant hand after appropriate warm-up.[12] Values below 27kg for men and 16kg for women trigger immediate concern, but more importantly, I track longitudinal changes in all patients.[4] Annual decline exceeding 1kg signals accelerating metabolic dysfunction requiring urgent intervention regardless of other cardiovascular risk parameters.[6]

The therapeutic response involves comprehensive metabolic reset targeting muscle function and body composition rather than traditional pharmaceutical approaches alone. Progressive resistance training forms the cornerstone of this intervention, but the prescription must be specific and evidence-based rather than generic fitness advice.[13] I recommend structured sessions lasting fifteen minutes, four times weekly, focusing on compound movements that engage multiple large muscle groups simultaneously. This includes bodyweight squats, modified push-ups, and resistance band exercises that patients can perform without expensive equipment or gymnasium membership.

The key principle is progressive overload gradually increasing resistance or repetitions to continuously stimulate muscle adaptation.[13] Most patients resist this approach initially, expecting purely pharmaceutical solutions to their cardiovascular risk. However, the evidence for cardiovascular benefits of strength training often exceeds those of medications we routinely prescribe.[11] The biological mechanisms prove equally compelling patients who complete twelve weeks of progressive resistance training demonstrate measurable improvements in insulin sensitivity, inflammatory marker profiles, and arterial function that persist for months after training cessation.[13]

Nutritional intervention proves synergistic with resistance training in optimising cardiovascular outcomes.[5] The evidence strongly supports increased protein intake combined with carbohydrate reduction to drive favourable body recomposition. I typically recommend 1.2-1.6g protein per kilogram body weight daily, emphasising complete proteins that provide essential amino acids for muscle protein synthesis.[5] This approach specifically targets visceral adipose tissue reduction while preserving lean muscle mass, addressing the root cause of cardiovascular inflammation rather than managing downstream consequences.[5]

For patients with significant metabolic dysfunction, I now incorporate GLP-1 receptor agonists as part of this metabolic reset approach. These medications prove extraordinarily effective at reducing visceral adipose tissue when combined with resistance training, creating powerful synergy for coronary risk reduction that extends far beyond glucose control.[7]

Bottom Line

The relationship between grip strength and cardiovascular health represents the most important paradigm shift in preventive cardiology that I have witnessed during three decades of clinical practice. This simple measurement provides immediate insight into muscle function, inflammatory status, and metabolic health that transforms our understanding of coronary disease prevention.[1,2] Rather than focusing solely on traditional risk factors, we must address the underlying muscle-metabolic dysfunction that drives cardiovascular disease through multiple causal pathways that we can now measure and target therapeutically.[8,9]

The therapeutic implications extend beyond exercise prescription to comprehensive metabolic reset targeting the biological mechanisms that either protect or damage the cardiovascular system.[15] Progressive resistance training combined with appropriate nutritional intervention restores muscle function and the protective myokine profile that actively combats atherosclerosis.[13,17] This approach often provides greater cardiovascular benefit than optimising traditional pharmacological interventions alone, particularly when addressing root causes rather than downstream effects.[11]

The evidence base now supports grip strength measurement as routine cardiovascular risk assessment, with declining strength serving as an early warning system for disease acceleration that appears years before traditional markers demonstrate meaningful changes.[1,2] This represents fundamental shift from reactive treatment toward proactive intervention targeting the biological pathways that drive cardiovascular pathology.

TAKEAWAYS:

1. Grip strength measurement provides more accurate cardiovascular risk prediction than traditional markers because it reflects the functional integrity of skeletal muscle as an endocrine organ that either protects or damages the cardiovascular system through myokine secretion.[1,8]
2. Declining muscle strength drives coronary heart disease through multiple causal pathways including reduced protective myokine production, increased systemic inflammation, and accelerated visceral adipose tissue accumulation that can be measured and targeted therapeutically.[9,16]
3. Progressive resistance training for fifteen minutes four times weekly combined with increased protein intake creates measurable cardiovascular protection by restoring muscle function and optimising body composition through mechanisms distinct from traditional pharmaceutical interventions.[13,5]
4. Annual grip strength decline exceeding 1kg signals accelerating metabolic dysfunction requiring immediate intervention regardless of other risk factors, providing early warning system for cardiovascular disease progression that appears years before traditional markers change.[6]

REFERENCES

1. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A Jr, Orlandini A, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-73. doi:10.1016/S0140-6736(14)62000-6
2. Celis-Morales CA, Welsh P, Lyall DM, Steell L, Petermann F, Anderson J, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651. doi:10.1136/bmj.k1651
3. Garcia-Hermoso A, Cavero-Redondo I, Ramirez-Velez R, Ruiz JR, Ortega FB, Lee DC, et al. Muscular strength as a predictor of all-cause mortality in an apparently healthy population: a systematic review and meta-analysis of data from approximately 2 million men and women. Arch Phys Med Rehabil. 2018;99(10):2100-13. doi:10.1016/j.apmr.2018.01.008
4. Bohannon RW. Grip strength: an indispensable biomarker for older adults. Clin Interv Aging. 2019;14:1681-91. doi:10.2147/CIA.S194543
5. Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127(6):547-53. doi:10.1016/j.amjmed.2014.02.007
6. Peterson MD, Duchowny K, Meng Q, Wang Y, Chen X, Zhao Y. Low normalized grip strength is a biomarker for cardiometabolic disease and physical disabilities among U.S. and Chinese adults. J Gerontol A Biol Sci Med Sci. 2017;72(11):1525-31. doi:10.1093/gerona/glx031
7. Lopez-Jaramillo P, Cohen DD, Gomez-Arbelaez D, Bosch J, Dyal L, Yusuf S, et al. Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. Int J Cardiol. 2014;174(2):458-61. doi:10.1016/j.ijcard.2014.04.013
8. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457-65. doi:10.1038/nrendo.2012.49
9. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012;28(5):495-503. doi:10.1016/j.nut.2011.12.002
10. Patel HP, Syddall HE, Jameson K, Robinson S, Denison H, Roberts HC, et al. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing. 2013;42(3):378-84. doi:10.1093/ageing/afs197
11. Artero EG, Lee DC, Ruiz JR, Sui X, Ortega FB, Church TS, et al. A prospective study of muscular strength and all-cause mortality in men with hypertension. J Am Coll Cardiol. 2011;57(18):1831-7. doi:10.1016/j.jacc.2010.12.025
12. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423-29. doi:10.1093/ageing/afr051
13. Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: a narrative review. Eur J Intern Med. 2015;26(5):303-10. doi:10.1016/j.ejim.2015.04.013
14. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S157-63. doi:10.2337/dc09-S302
15. Schnyder S, Handschin C. Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. Bone. 2015;80:115-25. doi:10.1016/j.bone.2015.02.008
16. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol. 2015;11(2):86-97. doi:10.1038/nrrheum.2014.193
17. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8. doi:10.1038/nature10777

Related blog articles

1. Cardiologist Body Recomposition https://www.scvc.co.uk/cardiovascular-prevention/cardiologist-body-recomposition/
2. Habit Stacking Metabolic Health https://www.scvc.co.uk/vat/habit-stacking-metabolic-health/

Surrey Cardiovascular Clinic  ·  scvc.co.uk  ·  01483 467100  ·  enquiries@scvc.co.uk  ·  © 2026